Publications
A phase 1 study of the IAP inhibitor xevinapant (Debio 1143) to evaluate food effect and drug-drug interactions with a…
3-Years follow-up results of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus Debio 1143 (xevinapant) or placebo in…
Safety and efficacy of Xevinapant (Debio 1143), an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in…
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind,…
Debio 1143 Mode of Action: a Broad Chemo-Radio and Immuno-Therapy Sensitizer
A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid…
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the smac mimetic Debio 1143 in patients…
DEBIO 1143, an IAP inhibitor, reverses ovarian cancer cells carboplatin resistance and triggers apoptotic or necroptotic cell death